Boston- and London-based health and nutrition app Zoe raised a £25M Series B extension led by Accomplice at a £209M valuation, after a £48M Series B in May 2021
Context & Ripple Effects
Zoe is topping up its £48M Series B from May 2021 with a £25M extension led by Accomplice, holding a £209M valuation rather than resetting it upward — a structure that reads as bridge capital in a harder funding market than the one that priced its last round.
First-order effects
- Zoe extends its runway into 2023 without a down round, while Accomplice takes a lead position in personalized nutrition at a flat-ish valuation.
Second-order effects
- Rivals in app-based diet and metabolic care face the same repricing: Oviva raised $80M at Series C and Found took $100M at a $600M valuation in the 2021 market, so both now compete against a peer that just accepted a materially lower mark to keep spending.
Third-order effects
- If extension-at-flat becomes the norm for consumer health apps, the sector consolidates around companies that convert clinical credibility into payer or employer contracts before growth capital dries up.
The trend: Consumer health apps are shifting from growth-priced rounds to extension financing, separating the category's 2021 valuations from what investors will pay in 2022.